Skip to main content
Equibles
ADAPY logo

ADAPY · Adaptimmune Therapeutics PLC

Track ADAPY — free

Use ADAPY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.03 +0.01 (+22.81%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2025

Substantial doubt about the company's ability to continue as a going concern.

“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”
View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.03 Open$0.03 Day$0.02–0.03 52W close$0.00–0.22 Avg vol 30d152K Short int1.2M · 0.1% float · 5.6d Short vol18% Last earningsMay 13, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2025

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +4%
above
Price vs 50-day avg −13%
below
RSI (14) 50
neutral
MACD trend Negative
52-week position 12%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −13%
trailing
6-month return +180%
trailing
YTD return +8%
this year
Relative strength +167%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Distributing
-91% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.08% of float · ▼ -0.0% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score 38
low risk · 0–100
Fundamentals
Strong
Revenue growth +195%
Y/Y
EPS growth +44%
Y/Y
Free cash flow $-74.1M
Balance sheet $36.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 1517%
annualized · 1-yr
Max drawdown −100%
past year
ATR 25.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 13, 2024
Aggregate cost savings · over the next four years $300M
Prior guidance period ended · from the 8-K filed May 13, 2025
Tecelra sales · 2025 full year $35M – $45M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+4% Bullish
Price vs 50-day avg
−13% Bearish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
12% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Distributing
-91% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.08% of float · ▼ -0.0% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 12% Range high $0
vs 200-day avg +4% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADAPY
Adaptimmune Therapeutics PLC
this stock
$44.53M +7.7% +195.3% — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Net QoQ
-1.7M sh
Top holder
RHUMBLINE ADVISERS
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
1.2M
Days to cover
5.6d
Change
-5 sh
View
Short Volume
Short vol %
18%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1.9K
Value
$56
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$178.0M
Net income (FY)
$-70.8M
EPS diluted
$-0.05
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 20, 2025
This year
0
View
Proposed Sales
Value
$942
Shares
16.0K
Filed
Sep 2, 2025
View
Earnings & Events
Earnings Calls
Last call
May 13, 2025
View

Performance

5D 20D 120D MTD YTD
ADAPY +3.7% -12.5% +180.0% -12.5% +7.7%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY +3.2% -15.5% +166.6% -15.5% -5.1%
Key facts CIK 1621227 CUSIP 00653A107 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)